about
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatmentNon-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and MouseKinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effectsCardiotoxicity following cyclophosphamidetherapy: a case reportEvidence-based guidelines for empirical therapy of neutropenic fever in Korea.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activityCardiovascular effects of noncardiovascular drugs.Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.Biological drugs: classic adverse effects and new clinical evidences.Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine.Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited.Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis.Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures.Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Prevalence of in-hospital nonsteroidal antiinflammatory drug exposure in patients with a primary diagnosis of heart failure.
P2860
Q26766318-87BC0841-108E-49DC-8F3F-8A46473E6AF0Q28079801-2129636A-EDAB-43AC-9D15-A728E14D4070Q28748600-6A1C598D-CE32-462B-95F4-2CCDB08C70FFQ33930737-82B4E830-6A31-40FF-AB46-DB150F4B60F9Q35033597-A78E06FE-8E17-42E0-9F74-88CC6936DACCQ35490056-6579D26F-E14F-44F1-8453-92EF4A464C27Q36654882-2C86C497-E2DC-4025-8811-8FA4464E27BFQ37413163-645909EB-D978-45BC-91C5-7BDD5B75B345Q37989562-EA249E71-0565-46E3-BEA9-C4016BA45AA2Q38015746-27125B7A-349F-4CBC-8857-1BDEA4C800A2Q38335622-F7BAA33D-0BCB-4F81-A30A-6BE7CBA09746Q38973323-607DD452-C602-4C8C-912E-295EE223EDA9Q39030459-B394A110-95D8-4EF0-A5FF-C7C01B64250CQ39033784-BDDDE7AA-2327-4CA9-95CE-052E80199AC7Q39672399-4B41C3FB-2066-495D-B8F0-27F330ED47E9Q40987491-2923C8D8-16D3-4750-A312-1E33BFDB5811Q42709339-7DFFABB6-FC1F-4290-A782-68E7CE949C1BQ45022373-A957DA62-6FAE-4114-832D-4ADEAE8BAD07Q45073135-13B1D2BF-90FD-41D6-A88E-DE4A0D1ECF5EQ48193986-E328540D-46A5-47B1-A914-369EAEA661CB
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Heart failure induced by non-cardiac drugs.
@ast
Heart failure induced by non-cardiac drugs.
@en
type
label
Heart failure induced by non-cardiac drugs.
@ast
Heart failure induced by non-cardiac drugs.
@en
prefLabel
Heart failure induced by non-cardiac drugs.
@ast
Heart failure induced by non-cardiac drugs.
@en
P2860
P1433
P1476
Heart failure induced by non-cardiac drugs.
@en
P2860
P304
P356
10.2165/00002018-200629070-00003
P577
2006-01-01T00:00:00Z
P6179
1053341227